Navigation Links
Consortium gets $7.2 million contract renewal to promote phase II clinical trials
Date:10/28/2011

TAMPA, Fla. -- The National Cancer Institute recently awarded $7.2 million for the competitive renewal of the Southeast Phase 2 Consortium (SEP2C), led by Moffitt Cancer Center's Daniel Sullivan, M.D., executive vice president and associate center director for Clinical Investigations. The renewal is through September 2016.

The SEP2C enrolls patients to phase II clinical trials and some phase I trials across six member sites. Moffitt is the lead site for the large contract that is awarded through the NCI's N01 research and development contract mechanism. The first year is projected to provide nearly $1.5 million.

The other member sites are UNC Lineberger Comprehensive Cancer; Vanderbilt-Ingram Cancer Center; Winship Cancer Institute of Emory University; VCU Massey Cancer Center; and the Cancer Institute of New Jersey.

Patient accrual at Moffitt will be focused on the following cancers: acute myeloid leukemia, breast, colorectal, lung, myelodysplastic syndrome, melanoma, multiple myeloma, non-Hodgkin's lymphoma, ovarian and sarcoma, as well as on immunotherapy and novel phase I trials. The consortium provides full management of the clinical trials including initiation, assessing eligibility, recruitment, evaluation of toxicity and response, auditing, follow-up, and analysis of results.


'/>"/>
Contact: Ferdie DeVega
Ferdinand.DeVega@moffitt.org
813-745-7858
H. Lee Moffitt Cancer Center & Research Institute
Source:Eurekalert

Page: 1

Related medicine news :

1. Einstein researcher helps lead consortium for $10 million X Prize to sequence genomes of 100 centenarians
2. University of Delaware to lead DoD orthopaedic rehabilitation consortium
3. Hutchinson Center receives $8.2M to coordinate obesity and cancer consortium
4. BIDMC to co-lead NIH consortium for AIDS vaccine research in nonhuman primates
5. ALK rearrangement found in nearly 10 percent of patients in Lung Cancer Mutation Consortium
6. Scripps Translational Science Institute joins Jackson Laboratory tumor consortium
7. Consortium identifies genome regions that could influence severity of cystic fibrosis
8. Biodesign hosts international consortium on screening for lung cancer
9. LSTM leads new £6 million ($9.3 million) health systems knowledge consortium
10. International consortium to examine the impact of medical devices on health and retirement
11. NCI awards $11.5 million to Fred Hutchinson Cancer Research Center to lead breast cancer consortium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... 2017 , ... Accreditation Commission for Health Care (ACHC) is ... (HCAOA). This agreement allows HCAOA members to receive special pricing on ACHC’s Home ... University (AU) educational resources that help prepare HCAOA members for ACHC Accreditation. , ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... to announce the integration of Microsoft(R) Word(TM) Online(TM), which enables sleep physicians to ... since it streamlines the reporting process and provides a familiar interface that does ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... Horizon Blue ... affirmed the company’s credit rating of “A” and its outlook as “stable.” At the ... capital reserves, which have fallen in recent years, dip below “capital adequacy” thresholds required ...
(Date:4/28/2017)... ... April 28, 2017 , ... GlycoMark, Inc. announced today ... throughout the Northeast U.S. , GlycoMark is the only clinically available blood ... provides a clinically proven one- to two-week measure of hyperglycemic excursions, often related ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... . These lamps offer an instant energy-saving solution for F32T8 fluorescent lamps on ... or disconnect ballasts. These 50,000 hour rated lamps utilize the existing electronic ballast, ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... NEW YORK , April 19, 2017 /PRNewswire/ ... This report on the prostate cancer ... of the global market. Increasing prevalence of prostate ... as innovation in the development of new drugs ... hormone-refractory prostate cancer drug due to lesser side ...
(Date:4/19/2017)... PUNE, India , April 19, 2017 ... Type and Application, Forecast to 2022 report has covered and ... provides statistics and information on market size, shares and growth ... with major drivers, challenges and opportunities in the global market. ... Browse 152 Tables and ...
(Date:4/19/2017)... , April 19, 2017 ... stimulate an immune response in pets such as ... products are of various types such as Attenuated ... Toxoid Vaccines, DNA Vaccines and Recombinant Vaccines. Attenuated ... as virus or bacteria, which have been weakend ...
Breaking Medicine Technology: